All In Biotech

Drug Trial Radar · NCT06830798

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

May 19, 2025

Primary completion

Nov 30, 2027

Study completion Aug 30, 2028

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

Conditions

  • Delayed Graft Function
  • DGF
  • Kidney Transplant

Interventions

  • RavulizumabDrug

    Participants will receive ravulizumab via intravenous (IV) infusion.

  • PlaceboDrug

    Participants will receive placebo via intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Freedom from DialysisTime frame: Through 90 days post-transplant

Locations

130 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    San Francisco, California · Withdrawn

  • Research Site

    San Francisco, California · Recruiting

  • Research Site

    Stanford, California · Recruiting

  • Research Site

    New Haven, Connecticut · Recruiting

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Tampa, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Fairway, Kansas · Recruiting

  • Research Site

    Lexington, Kentucky · Recruiting

  • Research Site

    Kenner, Louisiana · Recruiting

  • Research Site

    Ann Arbor, Michigan · Recruiting

  • Research Site

    Detroit, Michigan · Recruiting

  • Research Site

    Minneapolis, Minnesota · Recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    Omaha, Nebraska · Recruiting

  • Research Site

    Livingston, New Jersey · Recruiting

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Durham, North Carolina · Recruiting

  • Research Site

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Greenville, South Carolina · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Dallas, Texas · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Charlottesville, Virginia · Recruiting

  • Research Site

    Richmond, Virginia · Recruiting

  • Research Site

    Seattle, Washington · Recruiting

  • Research Site

    Milwaukee, Wisconsin · Recruiting

  • Research Site

    Buenos Aires, Argentina · Recruiting

  • Research Site

    Buenos Aires, Argentina · Recruiting

  • Research Site

    Buenos Aires, Argentina · Recruiting

  • Research Site

    Capital Federal, Argentina · Not yet recruiting

  • Research Site

    Córdoba, Argentina · Recruiting

  • Research Site

    Adelaide, Australia · Recruiting

  • Research Site

    Brisbane, Australia · Recruiting

  • Research Site

    Camperdown, Australia · Recruiting

Showing 40 of 130 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.